Pirfenidone use in fibrotic diseases: What do we know so far?
Authors:
- Aldo TorreATAldo Torre
- Froylan David Martínez‐SánchezFMFroylan David Martínez‐Sánchez
- Sofía Mercedes Narvaez‐ChávezSNSofía Mercedes Narvaez‐Chávez
- Mariana Ariel Herrera‐IslasMHMariana Ariel Herrera‐Islas
- Carlos Alberto Aguilar‐SalinasCACarlos Alberto Aguilar‐Salinas
- Jacqueline Córdova‐GallardoJCJacqueline Córdova‐Gallardo
Top Cited Papers
Open Access
- 5 July 2024
- journal article
- review article
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 12 (7) , e1335
Abstract
Background: Pirfenidone has demonstrated significant anti‐inflammatory and antifibrotic effects in both animal models and some clinical trials. Its potential for antifibrotic activity positions it as a promising candidate for the treatment of various fibrotic diseases. Pirfenidone exerts several pleiotropic and anti‐inflammatory effects through different molecular pathways, attenuating multiple inflammatory processes, including the secretion of pro‐inflammatory cytokines, apoptosis, and fibroblast activation.Objective: To present the current evidence of pirfenidone's effects on several fibrotic diseases, with a focus on its potential as a therapeutic option for managing chronic fibrotic conditions.Findings: Pirfenidone has been extensively studied for idiopathic pulmonary fibrosis, showing a favorable impact and forming part of the current treatment regimen for this disease. Additionally, pirfenidone appears to have beneficial effects on similar fibrotic diseases such as interstitial lung disease, myocardial fibrosis, glomerulopathies, aberrant skin scarring, chronic liver disease, and other fibrotic disorders.Conclusion: Given the increasing incidence of chronic fibrotic conditions, pirfenidone emerges as a potential therapeutic option for these patients. However, further clinical trials are necessary to confirm its therapeutic efficacy in various fibrotic diseases. This review aims to highlight the current evidence of pirfenidone's effects in multiple fibrotic conditions.Keywords
This publication has 103 references indexed in Scilit:
- Potent antioxidant role of Pirfenidone in experimental cirrhosisEuropean Journal of Pharmacology, 2008
- Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental GlomerulosclerosisClinical Journal of the American Society of Nephrology, 2007
- A pilot study in patients with established advanced liver fibrosis using pirfenidoneGut, 2006
- Pirfenidone: Anti-fibrotic agent with a potential therapeutic role in the management of transplantation patientsEuropean Journal of Pharmacology, 2006
- Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1β at a step of NF-κB DNA binding in hepatocytesJournal of Hepatology, 2004
- Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in ratsJournal of Hepatology, 2004
- Pirfenidone effectively reverses experimental liver fibrosisJournal of Hepatology, 2002
- Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA‐salt hypertensive ratsBritish Journal of Pharmacology, 2002
- Pirfenidone in the Treatment of Primary Sclerosing CholangitisDigestive Diseases and Sciences, 2002
- Pirfenidone improves renal function and fibrosis in the post-obstructed kidneyKidney International, 1998